Cardinal Health’s Post

🌐 Part 3 of this #GlobalBiosimilarsWeek series dives into interchangeability—a key factor for biosimilar adoption. Written by Dracey Poore of Cardinal Health, this article explores how interchangeability could impact access to affordable treatment options. While #biosimilars are proven safe and effective, complex policies and costs hinder their path to patients. With new FDA guidance potentially reducing the burden of switching studies, the future may hold quicker access and broader savings. Join us in advocating for a biosimilar-friendly health care landscape! 🔗 Read more: https://lnkd.in/e9f44wWf

Patient access to safe and effective treatments is critical, this is why biosimilars are so important. In the article below for Center for Biosimilars, I dive into the impact of the interchangeability designation on patient access to biosimilars. #GlobalBiosimilarsWeek

2024 US Generic & Medicines Savings Report, “in 2023, savings from the use of biosimilars increased by more than 30 percent from the previous year, to $12.4 billion. Since their entry to market in 2015, biosimilars have generated $36 billion in savings for America’s patients and the US health care system.” By removing barriers for biosimilar manufacturers, increasing speed to market and by increasing patient education and awareness around biosimilars as a safe and effective treatment option, we can increase patient access to these medicines and bring down total costs to the health care system.--- This is something we are actively discussing with our members. If you would like to know more or how to access biosims at a contracted rate for your practice, please let me know! #biosim #biosimilar #rhuematology #AIC #infusion #specialtypharmacy #healthcare #patientfirst #cencora #specialtypracticenetwork

The Future of Health Care: Insights from Eric Palmer at #EvernorthOutcomes  Eric Palmer, President and CEO of Evernorth Health Services, recently shared his vision for the future of health care. Key topics included reducing drug prices, the role of biosimilars, and improving patient access through enhanced guidance. These are crucial steps toward a more efficient and equitable system. Watch the full video for more insights: https://lnkd.in/gzCeJEAn #HealthCareInnovation #Biosimilars #MedMind #AccessToCare #PatientOutcomes

This systematic review by Chad Rieger and colleagues summarises the enablers and barriers affecting uptake of biosimilars through the application of a classification system to organise them into healthcare professional, patient, or systemic categories. #biosimilars #actornetworktheory #openaccess https://lnkd.in/gQ7MNxy5

💡Free Virtual Event 👉🏼 Futureproofing Biosimilars and Expanding Patient Access: Discuss the U.S. biosimilars market, the value biosimilars provide to patients, how these medicines fit into the health care system — and what needs to be done to advance adoption. #PatientAccess #Healthcare #Biosimiliars #HealthData #HealthcareSystem

Discover the Future of Healthcare Delivery with #PrefilledSyringes! Join us and explore our blog, which highlights the following key points: • #MarketGrowth: Projected to reach $22.8 billion by 2029. • #WhyItMatters: Enhanced safety, precision, and convenience for patients. • #DrivingFactors: Innovations in biology, rising chronic disease prevalence. • #KeyPlayers: BD, Baxter, Stevanato Group, and more leading the charge. Explore further by visiting the blog's link: https://bit.ly/3VYJhjU #InjectionDevices #MedTech #PharmaTech #PatientSafety #MarketTrends #MarketGrowth

As all of us are patients, we can now observe our own autonomy in health issues. ✅ Statistics prove that 80% of patients research their diagnoses online before visiting the healthcare institution. There's nothing strange about that fact, as the online environment is full of easily accessible information. Rather than ignoring this trend, we need to embrace these changes and use them to boost patient experience in pharma. 👉🏻 What's the action plan? Our team has identified six ways to shift the focus from selling to satisfying patient needs. And now it's just one click away: https://lnkd.in/dAa4tPUq

A purpose second to none As the global burden of chronic disease grows unabated and healthcare systems are facing formidable challenges to cope with the needs of ageing populations, AZ’s BioPharmacuticals Medical team aims to partner with healthcare systems to transform how care is delivered. Our vision is that in the future we will have health systems where patients are diagnosed early and disease prevention is prioritised. Systems in which high-risk patients can be identified for personalised care and where clinical trial access is part of the whole healthcare delivery model. And finally, where healthcare systems are de-carbonised to enable environmentally sustainable healthcare. We do this in partnership with healthcare systems, driving early screening and diagnosis of at-risk patients, supporting the adoption of ambitious clinical guidelines, delivering practice-defining clinical trials and real-world data, and accelerating pipeline delivery - up to and then beyond product launch. https://lnkd.in/dmsM6k4A Careers site: https://lnkd.in/eXff8Hyt Timothy Geldard Alex de Giorgio-Miller April Bergeron Guillermina Esparza Christos Manolis

"In a time when drug price inflation has become a critical factor affecting healthcare costs, our white paper provides actionable insights to empower decision-makers in navigating this complex terrain, ultimately leading to lower costs and better health outcomes." -Shane Garduno, VP of PBM Practice at Xevant. Read today's press release to learn more, and check the comments to access the white paper. 💊 📈